Eli Lilly

Johnson & Johnson

Sanofi

Large Drugmakers Show Resilience Amid Industry Challenges

强生

Johnson & Johnson's 15min Chart Triggers MACD Death Cross, KDJ Death Cross

British American Tobacco

The Coca-Cola

Dividend Stocks on the Rise: JNJ, BTI, and KO Amid Market Uncertainty

Barclays Increases Johnson & Johnson Price Target to $197, Maintains Equal Weight Rating

Johnson & Johnson Presents at Citi Annual Global Healthcare Conference 2025: Electrophysiology Market Trends and Future Outlook

Catalyst<ul> <li>Analyst ratings show a tendency toward optimism about JNJ despite some differences in opinion.</li></ul>Risk<ul> <li>Fund flows show a negative overall trend with large and extra-large investors pulling back from JNJ.</li> <li>Recent technical signals indicate overbought conditions in WR and RSI, suggesting potential for consolidation or pullback.</li></ul>

Key Factors

Barclays raised Johnson & Johnson's price target to $197 from $176, maintaining an Equal Weight rating.Johnson & Johnson's Tecvayli-Darzalex combination showed improved outcomes in multiple myeloma trials, prompting Guggenheim to reaffirm a Buy rating with a $206 price target.The European Commission approved Johnson & Johnson's Imaavy as an add-on treatment for generalized myasthenia gravis in adults and adolescents.Johnson & Johnson's Q3 sales increased 83.5% to $524 million, with the company projecting 5% annual revenue growth through 2030.Johnson & Johnson's Global Head of Heart Recovery discussed market trends in electrophysiology and the company's recent acquisitions during the Citi Annual Global Healthcare Conference 2025.

Recent Updates

JNJ News